Competition

A new OHE Briefing by Martin Chalkley (University of York) and Jon Sussex (RAND Europe) provides a view of the NHS ownership debate through the lens of economics.

To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?

A new OHE Seminar Briefing by Chris Mullin, Chief Economist at the Department of Health, examines growth in expenditure on NHS agency staffing.

OHE Lunchtime Seminar with Professor Martin Chalkley and Jon Sussex: Providing Health Care to NHS Patients: How Much Does Ownership Matter?

Drug prices in the US might overstate pharmaceuticals' long-run cost up to 75%. True long-term costs then must be considered by market access and policy decisions.

Professor David Grabowski from Harvard University will lead an OHE Lunchtime Seminar on 19 April 2017 on the topic of interventions that encourage high-value nursing home care: lessons for the UK.

A Research Paper on the topic of incorporating life-cycle price modelling into pharmaceutical cost-effectiveness evaluations has just been published by OHE.

This article looks at how theory could be put into practice suggesting ways to implement a differential pricing system for branded medicines in the EU that can enhance overall welfare.

Just published in Health Economics is an article by OHE’s Adrian Towse and others on pharmaceutical pricing in middle and low income countries (MLICs).

Dr. Aslam Anis, Director of the Centre for Health Evaluation and Outcomes Sciences (CHEOS) in Canada will undertake a short sabbatical with the Office of Health Economics in February 2015.

Pages

Subscribe to RSS - Competition